Charles River Laboratories International, Inc.
CRLHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeCharles River Laboratories International, Inc. operates in the Diagnostics & Research space. Charles River Laboratories International, Inc. With a market capitalization of $16.49B, it sits in large-cap territory. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
Market Cap
$16.49B
Beta
1.40
P/E (TTM)
—
P/E (Fwd)
27.10
EPS (TTM)
$-4.80
EPS (Fwd)
$12.75
ROE
-7.5%
ROA
4.1%
Cash
$192.0M
Total Debt
$3.03B
Free CF
$468.9M
52W Change
76.9%
Annual Financials
Cash vs Debt
Where CRL stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CRL finished 34.07% above its 150-day moving average ($223.78) and 39.16% above its 200-day moving average ($215.60). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRL overbought or oversold?
At the October 20, 2026 close, CRL's RSI(14) was 53.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, CRL has $192.0M in cash with $3.03B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $468.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -7.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.1% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $3.54B to $4.02B.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Charles River Laboratories International, Inc. and its sector.